India First Strategy Could Speed Up Data For FDA-EU Approvals - Mumbai Conference

MUMBAI - Pharmaceutical companies may be able to take advantage of the relative speed to market in India to commercialize products earlier and obtain postmarketing data that could bolster drug approval applications filed later in the U.S. and Europe, according to Biocon Founder and Chairman Kiran Mazumdar-Shaw

More from Archive

More from Scrip